Keywords: Boehringer Ingelheim, Pradaxa, Blood thinner, VTE, Pulmonary embolism, Warfarin
Positive trials results for Boehringer Ingelheim's Pradaxa for prevention of recurrent DVT and PE
Article | 22 February 2013
Findings from the RE-MEDY and RE-SONATE trials investigating German family-owned drug major Boehringer Ingelheim’s already marketed Pradaxa (dabigatran ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
